CCDC150 Inhibitors
CCDC150 inhibitors comprise chemicals that target a multitude of intracellular pathways, affecting the protein's function. For example, Ibrutinib acts on Bruton's tyrosine kinase (BTK), which may indirectly modify CCDC150 activity if the latter is part of signaling cascades involving BTK. Trichostatin A, a HDAC inhibitor, can impact gene expression profiles and might affect the transcriptional regulation of CCDC150. Wortmannin and Ly294002, both PI3K inhibitors, offer an alternate angle of affecting cellular pathways, altering CCDC150 function. GSK-3 Inhibitor IX, by inhibiting GSK-3, may modify Wnt and other signaling routes, incorporating CCDC150.
Moreover, Akt inhibitor MK-2206, Aurora kinase inhibitor ZM-447439, and mTOR inhibitor Rapamycin each present a distinct mechanism by which they can affect cellular functions and therefore CCDC150. Tofacitinib and Ruxolitinib, as JAK inhibitors, can interrupt cytokine-mediated signaling. These inhibitors collectively offer a comprehensive approach to affect CCDC150 function by impeding various cellular pathways in which this elusive protein may play a role. Through these different mechanisms of action, they provide a diversified strategy to study CCDC150 function more thoroughly.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
By inhibiting Bruton's tyrosine kinase (BTK), this compound can impact signaling pathways that CCDC150 may be involved in, consequently altering its functional state. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Known as a histone deacetylase (HDAC) inhibitor, which may impact the transcriptional regulation of CCDC150. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3K, thereby affecting multiple downstream pathways that may involve CCDC150. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
A tyrosine kinase inhibitor that can interfere with pathways where CCDC150 plays a role if it’s involved in protein phosphorylation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor that can potentially interrupt the MAPK signaling pathway, possibly involving CCDC150. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K inhibitor that can alter numerous cellular functions potentially linked with CCDC150. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
Inhibits GSK-3, which can alter Wnt and other signaling pathways where CCDC150 may function. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
Aurora kinase inhibitor that may affect mitotic processes, potentially involving CCDC150. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, affecting cellular growth and metabolism, processes that CCDC150 may have a role in. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Another JAK inhibitor, which affects cytokine-mediated signaling that may have CCDC150 involvement. | ||||||